Trials that use: Odds ratio
New to this method? Read the tutorial →
5,976 results
- TEACOIndependent statistical analysis of TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00296816).
- TEAMIndependent statistical analysis of A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TECTONICSIndependent statistical analysis of Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies: Complete Statistical AnalysisIndependent statistical analysis of Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142298).
- TELE001Independent statistical analysis of Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF): Complete Statistical AnalysisIndependent statistical analysis of Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03562247).
- Telephone-linked Home-based Exercise Training in PD: Complete Statistical AnalysisIndependent statistical analysis of Telephone-linked Home-based Exercise Training in PD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02898740).
- Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2): Complete Statistical AnalysisIndependent statistical analysis of Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00723827).
- Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00026494).
- Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy – Observational Program (Study P04816): Complete Statistical AnalysisIndependent statistical analysis of Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Temozolomide in Treating Patients With Low-Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide in Treating Patients With Low-Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00313729).
- Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea: Complete Statistical AnalysisIndependent statistical analysis of Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01020305).
- Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B: Complete Statistical AnalysisIndependent statistical analysis of Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM): Complete Statistical AnalysisIndependent statistical analysis of Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Tension Versus Tension- Free Foley Balloon for Cervical Ripening: Complete Statistical AnalysisIndependent statistical analysis of Tension Versus Tension- Free Foley Balloon for Cervical Ripening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05404776).
- Tepotinib Hepatic Impairment Trial: Complete Statistical AnalysisIndependent statistical analysis of Tepotinib Hepatic Impairment Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03546608).
- TESIndependent statistical analysis of The Safety and Efficacy of Nexalin Trans-cranial Electrical Stimulation Stimulation for the Treatment of Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TESSERACTIndependent statistical analysis of Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03574038).
- Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer:…
- Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya: Complete Statistical AnalysisIndependent statistical analysis of Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I): Complete Statistical AnalysisIndependent statistical analysis of Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers: Complete Statistical AnalysisIndependent statistical analysis of Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W): Complete Statistical AnalysisIndependent statistical analysis of Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F): Complete Statistical AnalysisIndependent statistical analysis of Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing Feasibility of Care Coordination and Motivational Interviewing for Women With a Recent Preterm Birth: Complete Statistical AnalysisIndependent statistical analysis of Testing Feasibility of Care Coordination and Motivational Interviewing for Women With a Recent Preterm Birth: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing Financial Incentive Interventions in Dyadic-Smoker Couples: Complete Statistical AnalysisIndependent statistical analysis of Testing Financial Incentive Interventions in Dyadic-Smoker Couples: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04832360).
- Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH – Subprotocol Z1K): Complete Statistical AnalysisIndependent statistical analysis of Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1): Complete Statistical AnalysisIndependent statistical analysis of Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates: Complete Statistical AnalysisIndependent statistical analysis of Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04565353).
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors: Complete Statistical AnalysisIndependent statistical analysis of Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03878095).
- Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH – Subprotocol Z1C): Complete Statistical AnalysisIndependent statistical analysis of Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer,…
- Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval,…
- Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma: primary endpoint results, effect…
- Testing the Effectiveness of a Falls Prevention System: Complete Statistical AnalysisIndependent statistical analysis of Testing the Effectiveness of a Falls Prevention System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03678402).
- Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening: Complete Statistical AnalysisIndependent statistical analysis of Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02495025).
- Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence…
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval,…